In nine of the 10 states, at least 15% of the population have GLP-1 prescriptions, according to insurance claims data
Paolisso G, Gambardella A, Tagliamonte MR, Saccomanno F, Salvatore T, Gualdiero P, DOnofrio MV, Howard BV
Keywords: glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, cardiovascular diseases, major adverse cardiovascular events, diabetes mellitus Introduction Despite major advance in treatment, cardiovascular diseases are still one of the leading causes of mortality and morbidity in the world
Inspections across the country found violations such as improper prescriptions and misleading marketing
A GLP-1-friendly meal plan emphasizes high fiber and protein intake to help maintain muscle mass and support metabolism